TORONTO, March 8, 2017 /CNW/ – Ascensia Diabetes Care Canada Inc. has announced the release of CONTOUR® NEXT ONE, an easy-to-use blood glucose monitoring system (BGMS) to help Canadians better manage their diabetes. The new meter is the next step in the evolution of self-monitoring of blood glucose with the aid of technology. The CONTOUR® NEXT ONE meter seamlessly connects to smart mobile devices, via the CONTOUR® Diabetes App, making it easy to review results and identify trends to understand how daily activities may impact blood glucose results.
“Technology can help simplify many elements of our daily lives – including diabetes management – by consolidating and helping to easily track what can seem like an overwhelming amount of information,” says Annika Pawaroo, Director of Consumer Marketing, Ascensia Diabetes Care Canada Inc. “71 per cent of people with diabetes own a smartphone and a growing number of patients are turning to smart mobile devices to help manage the disease and take an integrated approach to healthcare1.”
The launch of the CONTOUR® NEXT ONE system marks a new approach to diabetes management. The system features a wireless-enabled smart meter that links to a mobile device via Bluetooth®. The intuitive CONTOUR® Diabetes App collects, stores and analyzes patient blood sugar levels received from the meter. The meter results go beyond the minimum industry accuracy standards2 and is shown to deliver remarkable accuracy, with 95% of results coming within ±8.4%*3 of a laboratory reading. It features smartLIGHT technology using coloured lights to quickly indicate if a reading is too high, too low or within target range. And Second-Chance® sampling, a prompt for blood to be reapplied within 60 seconds if there is not enough the first time, helps to prevent wasted test strips. The captured blood glucose results can then be easily reviewed and shared effortlessly with healthcare professionals online; helping patients make more informed decisions and create better management plans.
“The launch of the CONTOUR® NEXT ONE blood glucose monitoring system is the latest of our high quality solutions, leveraging technology to meet the needs of the diabetes community,” says Pawaroo, “The system seamlessly integrates into the lives of those living with diabetes and has demonstrated consistently remarkable levels of accuracy for patients. At Ascensia Diabetes Care, we’re committed to helping improve the lives of people with diabetes to take their management of the disease to the next level.”
There are more than eleven million Canadians living with diabetes or prediabetes, and every three minutes another Canadian is diagnosed.4 The primary goal of diabetes management is to control blood sugar levels and ensure they are kept within a normal range. When blood glucose levels get too high (hyperglycemia) or too low (hypoglycemia), it can lead to serious complications and, in severe cases, even death.
“When we’re doing our daily blood sugar checks, we don’t always see the big picture, and so being able to connect whether it’s online or with specific apps gives us a better idea of what’s going on as a whole,” says Kayla Brown, patient living with diabetes for 8 years.
The CONTOUR® NEXT ONE system presents blood glucose readings in a simple, intuitive and easy-to-review way, which may help improve a patient’s engagement with and understanding of their condition. The system is also designed to evolve in the future, bringing new capabilities and features to help people with diabetes manage their condition.
About Ascensia Diabetes Care
Ascensia Diabetes Care was established in 2016 through the sale of Bayer Diabetes Care to Panasonic Healthcare Holdings Co., Ltd. Ascensia Diabetes Care products are sold in more than 125 countries. Following the close of the transaction in all countries, Ascensia Diabetes Care will have around 1,700 employees and operations in 38 countries.
Home to the world renowned CONTOUR™ portfolio of blood glucose monitoring systems, our products combine advanced technology with user-friendly functionality that help people with diabetes to manage their condition. We are committed to continued research, innovation and development of new products and solutions. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
For further information please visit the Ascensia Diabetes Care website at: www.contournextone.ca
CONTOUR® and Second-Chance® sampling are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG.
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks herein is under license.
_________________________________
*±8.4% applies to laboratory reference values for glucose concentrations
1 Multichannel ConsumerHealth Marketing 2015. Cybercitizen Health® Europe 2014, Bayer EU9
2 Current regulation based on Health Canada recognized ISO 15197:2013 standard requires results within ±15% range, specifically: ≥95% of results must fall within ±0.83 mmol/L for blood glucose concentrations 3 Christiansen M et al. Accuracy and user performance evaluation of a new blood glucose monitoring system in development for use with CONTOUR® NEXT test strips. Poster presented at the 15th Annual Meeting of the Diabetes Technology Society (DTS); 22–24 October, 2015; Bethesda, Maryland, USA
4 http://www.diabetes.ca/about-diabetes/types-of-diabetes
SOURCE The Colony Project
For further information: For media inquiries please contact: Stella Karami, The Colony Project, T: (416) 306-6739, E: stella.karami@colonyproject.com
RELATED LINKS
http://www.colonyproject.com/
